Lundbeck CEO expects migraine market to grow following Pfizer's billion-dollar acquisition
The USD 11.6bn acquisition bid for migraine firm Biohaven Pharmaceuticals would make Pfizer a direct competitor to Lundbeck. Even so, ”the migraine market is so big and so unsatisfied that there is room for multiple therapies,” says CEO Deborah Dunsire.
by christian bundgaard, translated by daniel pedersen
Lundbeck’s sales performance within its strategic brands was strong in the year’s first quarter, during which three out four of the firm’s key drugs beat analysts’ expectations.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Pfizer to acquire migraine firm for over USD 11bn
For subscribers
Lundbeck to delist in US
For subscribers
